eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

GlaxoSmithKline Consumer Healthcare

980 Great West Road, Brentford, Middlesex, TW8 9GS
Telephone: +44 (0)20 8047 5000
Medical Information Direct Line: +44 (0)20 8047 2500
Medical Information e-mail: customer.relations@gsk.com
Customer Care direct line: +44 (0)20 8047 2700
Medical Information Fax: +44 (0)20 8047 6860

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 17/10/2011
SPC Beechams Powders

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Date of revision of text on the SPC:   06-Jan-2011
Legal Category:   P, GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 2 removal of Ph Eur and correction of tablet to sachet

Section 4.2 addition of caution for use in elderly, and warning that product should be discontinued if pain gets worse or lasts more than 10 days, or if fever lasts more than 3 days

Section 4.3 all contra-indications with the exception of peptic ulcer, haemophilia and hypersensitivity to aspirin are new additions

Section 4.4 addition of first paragraph containing new special warnings and precautions including hypertension, renal and hepatic impairment, and warning to avoid excessive intake of caffeine

Section 4.5 all drug interactions with the exception of anticoagulants, methotrexate, oral hypoglycaemic agents and uricosuric agents are new additions

Section 4.6 amended from best avoided during late pregnancy and breast feeding to avoid during pregnancy and lactation, with relevant further information included

Section 4.8 complete revision of section

Section 4.9 revision of information relating to caffeine overdose, and management of overdose.  Specifically removal of administration of activated charcoal in the management of overdose and addition of no specific antidote available.

Updated on 18/03/2009 and displayed until 17/10/2011
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Date of revision of text on the SPC:  
Legal Category:   P, GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

None provided

Active Ingredients/Generics

 
   aspirin
   caffeine